Novel Drug Classes: Newer pharmacological agents, such as SGLT-2 inhibitors, initially developed for diabetes, have demonstrated significant cardiovascular and renal protective effects, including in diabetic cardiomyopathy, showcasing how advancements in drug therapy can complement lifestyle efforts in managing complex cardiometabolic conditions (130) While combined hypertension and diabetes intervention may not always significantly reduce CVD events, emphasizing comprehensive risk reduction remains paramount (131). The gene discussed is SLC5A2; the disease is diabetes mellitus.